HSBC Holdings’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$729K Buy
50,292
+1,951
+4% +$22.6K ﹤0.01% 2035
2025
Q4
$464K Buy
+48,341
New +$463K ﹤0.01% 2353
2024
Q2
Sell
-10,830
Closed -$275K 2925
2024
Q1
$275K Buy
10,830
+470
+5% +$11.4K ﹤0.01% 2496
2023
Q4
$232K Sell
10,360
-932
-8% -$19.3K ﹤0.01% 2398
2023
Q3
$209K Buy
+11,292
New +$234K ﹤0.01% 2397
2021
Q1
Sell
-6,797
Closed -$304K 2712
2020
Q4
$304K Buy
6,797
+991
+17% +$37.6K ﹤0.01% 2557
2020
Q3
$202K Sell
5,806
-67
-1% -$2.42K ﹤0.01% 2467
2020
Q2
$222K Buy
+5,873
New +$193K ﹤0.01% 2298

Other funds holding ANIK

HSBC Holdings's ANIK Position: Q1 2026 in Review

HSBC Holdings increased its Anika Therapeutics (ANIK) stake by 4% in Q1 2026, buying an estimated $22.6K and bringing the position to 50,292 shares worth $729K. The position accounts for ﹤0.01% of the portfolio, ranked #2035.

HSBC Holdings first reported a position in ANIK in Q2 2020 and has held it in 8 quarters since. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • HSBC Holdings held 50,292 shares of Anika Therapeutics worth $729K as of Q1 2026.
  • HSBC Holdings bought 1,951 Anika Therapeutics shares in Q1 2026, an estimated $22.6K.
  • Anika Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2035 holding.
  • HSBC Holdings first reported a position in Anika Therapeutics in Q2 2020 and has held it in 8 quarters since.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.